Synactix Pharmaceuticals, Inc.

Synactix is a biotechnology start-up specializing in the development of small-molecule "single agent pharmacology" therapies for human disease treatment. Synactix has licensed a cancer treatment based on novel compound capable of blocking multiple signaling proteins responsible for tumor growth which treats medullary thyroid cancer and shows further positive indications.
Team: 
Hong Yu Li
Brendan Frett
Massimo Santoro
Francesca Carlomagno
College: 
College of Pharmacy